Advertisement.

ORYZF Projected Dividend Yield

Ord/Oryzon Genomics SA ( OTCBB : ORYZF )

Oryzon Genomics is a clinical stage biopharmaceutical company engaged in developing and applying epigenetic personalized medicines for patients with cancer and central nervous system disorders. Co. has a broad portfolio, with two compounds in Phase II clinical trials: iadademstat (ORY-1001), a highly potent and selective Lysine specific demethylase 1 (LSD1) inhibitor that has been granted orphan-drug status by EMA, for oncology, and vafidemstat (ORY-2001), a CNS optimized LSD1 inhibitor for the treatment of neurological diseases.

20 YEAR PERFORMANCE RESULTS

ORYZF Dividend History Detail
ORYZF Dividend News
ORYZF Competitors News

# of Shares: 0

Closing Price: 1.69

Current Market Value: 0.00

Cost Basis: 0.00

Date Acquired:

Dividend Cash Flow
Year	Annual Dividend	Dividend Growth	# of Shares	Annual Dividend Income	Yield On Cost %
2014	0.00	0%	0	$ 0.00	0.00%
2015	0.00	0%	0	$ 0.00	0.00%
2016	0.00	0%	0	$ 0.00	0.00%
2017	0.00	0%	0	$ 0.00	0.00%
2018	0.00	0%	0	$ 0.00	0.00%
2019	0.00	0%	0	$ 0.00	0.00%
2020	0.00	0%	0	$ 0.00	0.00%
2021	0.00	0%	0	$ 0.00	0.00%
2022	0.00	0%	0	$ 0.00	0.00%
2023	0.00	0%	0	$ 0.00	0.00%
2024	0.00	0%	0	$ 0.00	0.00%
2025	0.00	0%	0	$ 0.00	0.00%
Using the current years Dividend Growth rate of 0% and projecting 0% forward the annual dividend income in 10/yrs would be $ 0.00 with a yield on cost % of 0.00%
Rolling Last 4 qtrs dividends total $ 0.00 and Previous last 4 qtrs dividends total $ 0.00
Dividend 1 Yr Growth = ( 0.00 – 0.00 ) × 100 = 0% (Click the Edit pencil if you want to modify the forward dividend growth rate projection) 0.00

Year	Declaration Date	Ex-Dividend Date	Record Date	Payable Date	Dividend $ Amount
Total:					0.0000